Entourage Health Corp. has announced the closing of its plan of arrangement with the LiUNA Pension Fund of Central and Eastern Canada (LPFCEC). As a result, Entourage has transitioned from being a publicly traded entity to a private company. The restructuring follows shareholder approval and final court authorization, marking a significant strategic shift for the Ontario-based cannabis company.
Under the deal, LPFCEC is to purchase all of the remaining common shares and convertible debentures of Entourage Health, uniting ownership under the pension fund and removing the company from the TSX Venture Exchange. In the case of George Scorsis, Executive Chairman and CEO of Entourage Health, the move represents a return to fundamentals and a focus on operational excellence.
“The closing of this arrangement helped us move forward with clarity and renewed direction. The arrangement provided the resources and strategic stability we needed to succeed within Canada’s maturing cannabis market,” says Scorsis.
Entourage has faced a series of industry challenges, including compressed margins, complex regulatory compliance, and shifting consumer demand. These pressures have driven consolidation across the sector and prompted many companies to reconsider their structure and financing. The decision to go private, Scorsis explained, was made to enable greater flexibility and long-term planning without the constraints of public-market expectations.
Scorsis has extensive experience in both cannabis and consumer packaged goods, previously holding senior executive roles in both industries. His leadership of Entourage has included successive waves of growth, portfolio advancement, and brand integration. Under his leadership, the company has released a wide variety of medical and adult-use cannabis and forged strategic partnerships within the distribution, retail and healthcare channels.
With its main operations based in Toronto, Entourage Health has established a reputation for producing high-quality cannabis and medical products. The company’s collaboration with the Starseed Medicinal platform, as well as its growing network of healthcare professionals and insurance providers, continues to support its presence in the medical cannabis space.
Scorsis, who has also worked extensively in Florida’s regulated market, said his experience in the United States has helped shape Entourage’s business model.
“My exposure to different regulatory environments has influenced how we approach compliance, product development, and customer service. That perspective, rooted in my experience in Florida, has helped us make informed decisions around efficiency and adaptability,” explains Scorsis.
The acquisition by LPFCEC provides Entourage with the capital needed to advance its growth initiatives. According to public documents, the pension fund has maintained a long-standing relationship with the company as a financial partner. The formal integration now allows for deeper alignment on governance, investment strategy, and future planning.
Upon the close of the transaction, Entourage intends to further scale up access for medical patients and create new cannabis and wellness products. The company’s executives have suggested that private ownership will allow them to make focused investments in offering cannabis to a broader range of patients through research, and technology without the immediate pressures of the capital market.
Entourage Health confirmed that trading of its shares has ceased and that it will no longer be subject to Canadian securities laws as a reporting issuer. Shareholders will be compensated as outlined in the plan of arrangement, and the company has published instructions for redeeming shares through its official channels.
“I want to thank our shareholders, partners, and employees for their support during the transition. We will continue to focus on providing safe, effective, and regulated cannabis products while contributing to the broader evolution of Canada’s cannabis sector,” says Scorsis.
With a clear ownership structure and stable financial backing, Entourage Health is entering its next phase with a commitment to long-term value creation and responsible industry leadership. The conclusion of the arrangement marks the start of a more focused and streamlined business strategy for the Toronto-based cannabis producer.
